---
title: "20/20 Biolabs, Inc. (AIDX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AIDX.US.md"
symbol: "AIDX.US"
name: "20/20 Biolabs, Inc."
industry: "Health Care Supplies"
datetime: "2026-05-21T02:34:05.743Z"
locales:
  - [en](https://longbridge.com/en/quote/AIDX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AIDX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AIDX.US.md)
---

# 20/20 Biolabs, Inc. (AIDX.US)

## Company Overview

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups.

| Item | Detail |
|------|--------|
| Industry | Health Care Supplies |
| Exchange | US Market |
| Website | [2020biolabs.com](https://2020biolabs.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.60)**

**Industry**: Health Care Supplies

| Metric | Value |
|--------|-------|
| Industry Ranking | 31 / 45 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 16.71% |  |
| Net Profit YoY | 32.65% |  |
| P/B Ratio | -211.51 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 14044367.27 |  |
| Revenue | 2045133.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -537.07% | E |
| Profit Margin | -182.82% | E |
| Gross Margin | 29.56% | C |
| Revenue YoY | 16.71% | B |
| Net Profit YoY | 32.65% | B |
| Total Assets YoY | 15.43% | B |
| Net Assets YoY | -101.28% | E |
| Cash Flow Margin | 51.35% | C |
| OCF YoY | 16.71% | B |
| Turnover | 0.53 | C |
| Gearing Ratio | 100.46% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - 20/20 Biolabs, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "16.71%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "32.65%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-211.51",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "14044367.27",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2045133.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-537.07%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-182.82%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "29.56%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "16.71%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "32.65%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "15.43%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-101.28%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "51.35%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "16.71%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.53",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "100.46%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.62 | 32/45 | - | - | - |
| PB | -203.61 | 43/45 | 644.99 | 457.57 | 317.43 |
| PS (TTM) | 6.61 | 36/45 | 14.18 | 9.26 | 7.84 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Essilor (ESLOY.US) | B | B | C | B | B | B |
| 02 | HOYA Corporation (HOCPY.US) | A | C | B | A | B | B |
| 03 | Align (ALGN.US) | B | C | B | B | C | B |
| 04 | Lantheus (LNTH.US) | A | C | B | C | C | B |
| 05 | Merit Medical (MMSI.US) | B | B | B | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.29 |
| Highest Target | 5.00 |
| Lowest Target | 5.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AIDX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AIDX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AIDX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AIDX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**